8-K: InMed Pharmaceuticals Granted Nasdaq Extension for Share Consolidation

InMed Pharmaceuticals has received an extension from Nasdaq to implement a share consolidation by December 2, 2024, to meet the minimum bid price requirement.

Summary

• InMed Pharmaceuticals was notified by Nasdaq that it did not meet the minimum $1.00 bid price per share requirement.
• The company requested a hearing to appeal the delisting notice and presented a plan to regain compliance.
• The Nasdaq Hearings Panel granted an exception, allowing InMed until December 2, 2024, to regain compliance.
• InMed's board approved a 1-for-20 share consolidation to increase the share price.
• The consolidation will reduce the number of outstanding shares from 14,361,550 to approximately 718,078.
• Shareholders will maintain the same percentage ownership after the consolidation.
• The company is working to complete the consolidation by the deadline, but there is no guarantee of success.

Sentiment

Score: 5

Explanation: The news is mixed, with a positive extension granted but a negative share consolidation required. The company is taking action to address the issue, but there is still uncertainty.

Positives

• The Nasdaq Hearings Panel granted InMed an extension to regain compliance.
• The company has a plan in place to meet the minimum bid price requirement through a share consolidation.
• Shareholders will maintain their percentage ownership after the consolidation.

Negatives

• InMed was initially notified of non-compliance with Nasdaq's minimum bid price rule.
• There is no guarantee that the company will meet the compliance deadline.
• The share consolidation will significantly reduce the number of outstanding shares.

Risks

• There is a risk that InMed may not be able to meet the minimum bid price requirement by December 2, 2024.
• Failure to meet the requirement could result in delisting from Nasdaq.
• The share consolidation may not be sufficient to maintain the share price above $1.00.

Future Outlook

The company is working to complete the share consolidation and regain compliance with Nasdaq listing rules by December 2, 2024, but there is no guarantee of success.

Management Comments

• InMed presented an overview of its current and ongoing strategic initiatives aimed at enhancing shareholder value and regaining compliance with the Minimum Bid Price Rule.

Industry Context

This announcement is specific to InMed's situation with Nasdaq listing requirements and does not reflect broader industry trends, although many small cap biotech companies face similar challenges with maintaining share price compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, particularly regarding minimum bid price requirements.
• Reverse stock splits are a common strategy for companies in this situation to regain compliance.
• Other companies that have recently undertaken reverse stock splits to maintain Nasdaq listing include XOMA Corporation and Agenus Inc.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they hold, but their percentage ownership will remain the same.
• The share consolidation is intended to increase the share price, which could benefit shareholders if successful.
• Failure to meet the compliance deadline could negatively impact shareholders.

Next Steps

• InMed will complete the share consolidation.
• The company must maintain a share price above $1.00 for ten consecutive trading days by December 2, 2024.
• InMed will continue to work on its strategic initiatives to enhance shareholder value.

Key Dates

Keywords

share consolidation, Nasdaq, minimum bid price, delisting, compliance, INM, pharmaceuticals